Primary bone lymphoma

C Pissarro C Azevedo*, P José AFF Tavares2, M Isabel P Portela1, A José LCP Santos2, J Manuel PS Casanova2

From 16th International Charles Heidelberger Symposium on Cancer Research Coimbra, Portugal. 26–28 September 2010

Background
Primary bone lymphoma (PBL) accounts for 3% of all primary bone malignancies [1] and represents <2% of all lymphomas in adults [2].

Material and Methods
Retrospective review of 25 patients with PBL treated at a single institution between 1995 and 2010.

Results
14 patients were female. The median age was 63 years (30-90). 13 had localized disease. The tumor had an axial location in 20 patients (80%). 6 patients presented with a pathologic fracture. The histological type was Non-Hodgkin Lymphoma B in all patients. There were 18 high grade lymphomas. According to the IPI, 8 cases (32%) were classified as low risk, 11 cases (44%) as intermediate risk and 6 (24%) as high risk. All patients received chemotherapy. 17 patients were treated with radiotherapy to a total dose that varied from 15 to 50 Gy. 7 patients underwent surgical treatment. The median follow-up was 12 months (1-121). Recurrence of the disease was seen in 3 patients. 9 patients had disease progression. With regard to the status of the patients: 8 patients are continuously disease free; 3 patients are alive with disease; 10 patients died of the disease; 2 patients died of other cause. The 10-year overall survival rate was 45%. The 5-year survival rate was 85% for low-risk IPI vs 35% for intermediate-risk IPI vs 18% for high-risk IPI.

Conclusions
Combined modality treatment results in good survival rates in patients with low-risk and intermediate-risk PBL.

References

do:10.1007/BF00192476